MEVPRO-1

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Dec 4, 2024 → Oct 16, 2026

Cited window

Dec 4, 2024 → Oct 1, 2026

Retrieved

Oct 18, 2026

Title

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

Registry

NCT06551324

Study IDs

C2321014 · 2024-511650-50-00 (CTIS (EU))

Sponsor

Pfizer

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

600 estimated

Start

2024-10-21 actual

Primary completion

2026-12-28 estimated

Primary endpoint

Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –Out of scope: 8 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –147 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition do not represent all HCPs or all public discussion, and trial-unnamed discussion may be underrepresented.
• –Some relevant discussion of PARP-combination alternatives and biomarker-based selection was not fully evaluated; the range of views may therefore be incomplete.
• –Repeated posts and multiple recordings of the same session cannot be counted as independent clinician opinions or separate clinical experiences.
• –Some speakers remain unidentified. Titles, participant lists and professional profiles do not establish who voiced those passages.
• –Clinical roles for Emir C. Roach, Rashid K. Sayyid and Rishabh Jain are not established in the sources reviewed. Patient, caregiver, publisher and financial commentary should not be treated as independent HCP judgment.
• –Earlier efficacy and safety observations are speaker reports from supporting studies, not MEVPRO-1 phase III outcomes. Differences in reported study phase and prior chemotherapy exposure remain unresolved.
• –Contemporaneous trial-design descriptions are inconsistent about the control comparison. The complete protocol was unavailable, so these remarks cannot resolve operational details.
• –An exact mevrometostat regulatory label was unavailable. Speaker descriptions of approvals, eligibility and reimbursement reflect their stated time and geography rather than independently verified current guidance.
• –Several numerical estimates concern selected databases, small groups, post-hoc analyses or individual experience; they do not support population-wide rates, causal comparisons or a treatment hierarchy.
• –Support-group treatment and insurance accounts are personal reports. They cannot establish comparative efficacy, molecular eligibility, payment guarantees or recommended self-directed treatment.

How reports are built and checked: Methods.

Last checked for new commentary Oct 19, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.